Live Long-Distance TeleRobotic Procedures to Highlight Stereotaxis Technology at Asia Pacific Heart Rhythm Symposium
August 16 2023 - 8:40AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced that its technology will be the focus of multiple live
long-distance telerobotic procedures at the upcoming Asia Pacific
Heart Rhythm Society (APHRS) Scientific Sessions.
APHRS and the Society for Cardiac Robotic
Navigation will host a joint session on September 2, 2023, during
the APHRS annual congress. The joint session includes
demonstrations of the unique capabilities and clinical value of
Stereotaxis’ robotic technology, including:
- A live long-distance telerobotic
pulmonary artery denervation procedure performed by Dr. Alexander
Romanov from the conference stage in Hong Kong on a patient in
Novosibirsk;
- Bi-directional live long-distance
telerobotic procedures by Dr. Ruxing Wang and Dr. Ke Chen,
concurrently treating patients with atrial fibrillation and
premature ventricular contractions at their respective hospitals in
Zhengzhou and Wuxi;
- Live navigation demonstration,
broadcast by Dr. Qi Jin from MicroPort EP’s headquarters in
Shanghai, of Stereotaxis’ Genesis Robotic Magnetic Navigation
system integrated with MicroPort EP’s Columbus mapping system and a
next-generation robotically-steered ablation catheter.
APHRS is the first society organized in the Asia
Pacific region to promote excellence and advancement in the
diagnosis and treatment of patients with heart rhythm disease. The
annual scientific sessions are the highlight of its activities.
They provide a platform for professional education, sharing of
cutting-edge science, demonstration of advanced and novel
techniques, and interaction among international experts in the
field of heart rhythm management. This year's sessions will be held
in Hong Kong on September 1-3, 2023.
The global physician-led Society for Cardiac
Robotic Navigation (SCRN) is dedicated to establishing a community
and platform for users of robotic technologies in cardiology. SCRN
provides opportunities for physicians and healthcare professionals
interested in advancing robotics to share best practices, discuss
new clinical literature, and evaluate the latest innovations in
technology.
"This joint session focuses on demonstrating
several futuristic capabilities of robotics that are increasingly
realistic and clinically relevant as we seek to advance
electrophysiology,” said Dr. Rahul Doshi and Dr. Qi Jin,
Electrophysiologists and SCRN Board Members. “We appreciate the
opportunity to collaborate and build a growing relationship between
SCRN and APHRS.”
“We look forward to unveiling for the first time
a comprehensive Stereotaxis and MicroPort EP product offering that
we expect will play a significant role in the field of EP in China
during the coming years,” said Dr. Sun Yiyong, President of
MicroPort EP.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global
leader in innovative surgical robotics for minimally invasive
endovascular intervention. Its mission is the discovery,
development and delivery of robotic systems, instruments, and
information solutions for the interventional laboratory. These
innovations help physicians provide unsurpassed patient care with
robotic precision and safety, expand access to minimally invasive
therapy, and enhance the productivity, connectivity, and
intelligence in the operating room. Stereotaxis technology has been
used to treat over 100,000 patients across the United States,
Europe, Asia, and elsewhere. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024